CLINICS 2010;65(5):547-54 6. 7. Ekbon K. Restless legs: a clinical study. Acta Med Scand. 1945;158:1- 122. Walters AS. Group organizer and Correpondent International Restless Legs Syndrome Study Group. Towards a better definition of the restless legs syndrome. Mov Disord. 1995;10:634-42. 8. St O’ Keeffe, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing. 1994;23:200-03. 9. J Krieger, C Schroeder. Iron status and restless legs syndrome. Sleep Medicine Reviews. 2001;5:277-86. 10. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome. Sleep Med 2004;4:385-91. 11. Huebers HA. Non hematological manifestations of iron deficiency. In Bo Lonnerdal, editor, Iron Metabolism in Infants, CRC Press, 1990;pgs 63-72. 12. Dallman PR, Goodman Jr. The effects of iron deficiency on the hepatocyte. A biochemical and ultrastructural study. JCB. 1971;48:79- 90. 13. Cupp MJ, Tracy TS. Cytochrome P450: New nomenclature and Clinical Implications. American Family Physician. 1998;57:117-26. 14. Feek CM, Sawers JSA, Brown NS, Seth J, Irvine WJ, Toft AD. Influence of thyroid status on dopaminergic inhibition of thyrotropin and prolactin secretion: evidence for an additional feedback mechanism in the control of thyroid hormone secretion. J Clin Endocrinol Metabol. 1980;51:585- 9. 15. Scanlon MF, Weetman AP, Lewis M, Pourmand M, Rodrigues A, Weightman DR. Dopaminergic modulation of circadian thyrotropin rhythm and thyroid hormone levels in euthyroid subjects. J Clin Endocrinol Metabol. 1980;51:1251-6. 16. G Delitala. Dopamine and TSH secretion in man. The Lancet. 1977;310:760-1. 17. Wojcikowski J, Gocen Biowska K, Wladystawa AD. Regulation of liver cythocrome P450 by activation of brain dopaminergic system. Biochem Pharmacol. 2008;76:258-67. 18. Meyer RP, Gehlhaus M, Knoth R, Volk B. Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab. 2007;8:297-306. 19. Brabant G, Prank K, Ranft U, Schuermeyer TOF, Wagner H, Hauser B, et al. Physiological regulation of circadian and pulsatile thyrotropin secretion in normal man and woman. J Clin Endocrinol Metab. 1990;70:403-9. 20. P. Lavie. Sleep-Wake as a biological rhythm. Annual Review of Psychology. 2001; pg277. 21. Guyton AC.Textbook of Medical Physiology. 7th Ed. W.B. Saunders Company, 1981. 22. Farwell AP, Braverman LE. Thyroid and Antithyroid Drugs. In Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Tenth edition. McGraw-Hill, New York, 2001;1563-96. 23. Parker DC, Rossman LG, Pekary AE, et AL. Effect of 64-hour sleep deprivation on the circadian waveform of thyrotropin (TSH): further evidence of sleep-related inhibition of TSH release. J Clin Endocrinol Metab. 1987;64:157-61. Copyright © 2010 CLINICS RLS: Imbalance between thyroid and dopamine Pereira Jr. JC et al. 24. Pannain S, Van Cauter E. Modulation of Endocrine Function by Sleep- Wake Homeostasis and Circadian Rhythmicity. Sleep Medicine Clinics. 2007;2:147-59. 25. Goichot B, Branderberg G, Saini J, Wittersheim G, and Follenius M. Nocturnal plasma thyrotropin variations are related to slow-wave sleep. J Sleep Res. 1992; 1:186-90. 26. Gronfier C, Luthringer R, Follenius M, Schaltembrand N, Macher JP, Muzet A, et al. Temporal link between plasma thyrotropin levels and electroencephalographic activity in man. Neurosci Lett. 1995;200:97-100. 27. Kaptein EM, Spencer CA, Kamiel MB, and Nicoloff JT. Prolonged dopamine administration and thyroid hormone economy in normal and critically ill subjects. J. Clin Endocrinol Metab. 1980;51:387-393. 28. Van den Berghe G, de Zeghert F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol.1994;41:731-7. 29. Debayeve YA, Van den Berghe GH. Is there still a place for dopamine in the modern intensive care unit? Anesth Analg. 2004;98:461-8. 30. Shupnik MA, Greenspan SL, Ridgway EC. Transcriptional regulation of thyrotropin subunit by thyrotropin-releasing hormone and dopamine in pituitary cell culture. J. Biol. Chem 1986;261:675-9. 31. Akpinar S. Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol. 1987;10:69-79. 32. Walters AS, Ondo WG, Dreykluft T, GrunsteinR, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome: TREAT RLS 2: a 12 –week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19:1414-23. 33. Walters A, Hening W, Kavey N, Chokroverty S, Sidro-Frank S. A Double-blinded randomized cross-over trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol. 1988;24:455-8. 34. Scanlon MF, Weightman DR, Shale DJ, Mora B, Heath M, Snow MH, et al. Dopamine is a physiological regulator of Thyrotropin (TSH) in normal man. Clin Endocrinol. 1978;10:7-15. 35. Filippi L, Pezzati M, Cecchi A, Poggi C. Dopamine infusion: A possible cause of undiagnosed congenital hypothyroidism in preterm infants. Pediat Crit Care Med. 2006;7:249-51. 36. Zhang GF, Tang YL, Smith AK, Zheng-gi L, Sheng LX, Yong C, et al. Alterations in pituitary-thyroid axis function among opioids-dependent subjects after acute and protracted abstinence. Addiction biology. 2009;14:310-4. 37. Ruzsas C, Mess B. Opioidergic regulation of thyroid activity: possible interference with the serotoninergic system. Psychoneuroendocrinology. 1983;8:89-94. 38. McNamara JO. Drugs effective in the therapy of the epilepsies. In Hardman JG, Limbird LE, Gilman AG, editors, The Pharmacological Basis of Therapeutics, tenth edition, 2001. McGraw-Hill, New York. 39. Indiana University Division of Clinical Pharmacology. Cytochrome P450 Drugs Interaction Table. Version. 5;2009. 40. Glinoer D. The regulation of thyroid function in pregnancy: Pathway of endocrine adaptation from physiology to pathology. Endocrine Reviews. 1997;18:404-33. 41. Dzaja A, Wehrle R, lancel M, Pollmacher T. Elevated estradiol plasma levels in women with restless legs during pregnancy. Sleep. 2009;32:169- 74. 553